Beyond Recycling Antibodies: Crovalimab’s Molecular Design Enables Four-Weekly Subcutaneous Injections for PNH Treatment

• Published in: International journal of molecular sciences Vol. 25; no. 21; p. 11679
• Main Authors: Sampei, Zenjiro, Haraya, Kenta, Gan, Siok Wan, Muraoka, Masaru, Hayasaka, Akira, Fukuzawa, Taku, Shida-Kawazoe, Meiri, Tsuboi, Yoshinori, Gotoh, Akihiko, Obara, Naoshi, Ueda, Yasutaka
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.11.2024; MDPI
• Subjects: Antibodies; Antigenic determinants; Antigens; Engineering; Patients; Pharmaceutical industry; Pharmaceuticals; Plasma; Proprietary; Single nucleotide polymorphisms; Viscosity; United States; Japan; United States > US

The advent of recycling antibodies, leveraging pH-dependent antigen binding and optimized FcRn interaction, has advanced the field of antibody therapies, enabling extended durability and reduced dosages. Eculizumab (Soliris®) demonstrated the efficacy of C5 inhibitors for paroxysmal nocturnal hemogl...